Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Influenza Vaccine in Breast Cancer
NCT06229392Phase 1Withdrawn
- Sponsor
- Rush University Medical Center
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) in breast cancer, sponsored by Rush University Medical Center. Primary endpoint: Dose-limiting toxicity at 3 months. Planned start Jun 2026; status: withdrawn.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06229392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229392.